Results 181 to 190 of about 192,885 (309)
Ecotypes of triple-negative breast cancer in response to chemotherapy. [PDF]
Yan Y +22 more
europepmc +1 more source
This study addresses the rapid renal clearance of anti‐HER2 nanobodies by developing specialized liposomal carriers. It details the formulation of dual modified liposomes, demonstrating how PEGylation preserves structural integrity and cell‐penetrating peptides enhance cellular interaction.
Giulia Pander +14 more
wiley +1 more source
Triple-negative breast cancer, pregnancy, and HLA alloreactivity: a cause for concern? [PDF]
Crestani Morassutti G, Zanetti M.
europepmc +1 more source
Triple-negative breast cancer in the elderly
Elena, Shagisultanova +2 more
openaire +2 more sources
Mechanism‐Informed Machine Learning Enables Discovery of Oncolytic Peptides for Cancer Immunotherapy
MISPOP integrates ensemble learning with membrane‐active physicochemical priors to identify Dermaseptin‐S9, a natural oncolytic peptide that disrupts tumor membranes, triggers immunogenic cell death, and shows strong antitumor activity. The study illustrates a mechanism‐informed route from peptide sequence data to cancer immunotherapy leads.
Wen Zhang +11 more
wiley +1 more source
Cepharanthine inhibits lysosomes and induces apoptosis in triple‑negative breast cancer cells. [PDF]
Li J +5 more
europepmc +1 more source
Triple‐negative breast cancer (TNBC) cells evade natural killer (NK) cell immunity by secreting IL8 and CXCL1. These chemokines suppress NK cells’ function via CXCR1/2 and enhance cancer cells’ survival through PD‐L1 upregulation and BCL‐2 anti‐apoptotic signaling.
Mingheng Yuan +6 more
wiley +1 more source
Triple-negative breast cancer: current understanding and future perspectives. [PDF]
Alobaidi A, Rai V.
europepmc +1 more source
Claudia Omarini, Giorgia Guaitoli, Stefania Pipitone, Luca Moscetti, Laura Cortesi, Stefano Cascinu, Federico Piacentini Department of Medical and Surgical Sciences for Children & Adults, Division of Medical Oncology ...
Cortesi L +6 more
core
A Plug‐and‐Play Platform for Customizing Multivalent Degraders and Degrader‐Drug Conjugates
Membrane proteins remain challenging targets for conventional TPD approaches. Here, the authors develop UPTAB, a modular platform leveraging ultrahigh‐affinity orthogonal Im/CL protein pairs for lysosomal degradation of membrane proteins. Mono‐targeted (Type‐I), dual‐targeted (Type‐II), and tri‐targeted (Type‐III) UPTABs enable simultaneous degradation
Mengqing Zhao +7 more
wiley +1 more source

